AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part III: Intraventricular Conduction Disturbances A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology

Borys Surawicz, Rory Childers, Barbara J. Deal, and Leonard S. Gettes


This information is current as of August 2, 2011

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://content.onlinejacc.org/cgi/content/full/53/11/976
The present article introduces the second part of “Recommendations for Standardization and Interpretation of the Electrocardiogram.” The project was initiated by the Council on Clinical Cardiology of the American Heart Association and has been endorsed by the American College of Cardiology Foundation, the Heart Rhythm Society, and the International Society for Computerized Electrocardiology. This statement was preceded by 2 articles, “The Electrocardiogram and Its Technology” and “Diagnostic Statements,” which were published previously (1,2), and it is followed by statements concerning abnormalities of repolarization, hypertrophy, and ischemia/infarction. The rationale for this initiative and the process by which it was achieved were described earlier (1).

The term intraventricular conduction disturbances refers to abnormalities in the intraventricular propagation of supraventricular impulses that give rise to changes in the shape and/or duration of the QRS complex. These changes in intraventricular conduction may be fixed and present at all heart rates, or they may be intermittent and be tachycardia or bradycardia dependent. They may be caused by structural abnormalities in the His-Purkinje conduction system or ventricular myocardium that result from necrosis, fibrosis, calcification, infiltrative lesions, or

Other members of the Standardization and Interpretation of the Electrocardiogram Writing Group include James J. Bailey, MD; Anton Gorgels, MD; E. William Hancock, MD, FACC; Mark Josephson, MD, FACC, FHRS; Paul Kligfield, MD, FAHA, FACC; Jan A. Kors, PhD; Peter Macfarlane, DSc; Jay W. Mason, MD, FAHA, FACC, FHRS; David M. Mirvis, MD; Peter Okin, MD, FACC; Olle Pahlm, MD, PhD; Pentti M. Rautaharju, MD, PhD; Gerard van Herpen, MD, PhD; Galen S. Wagner, MD; and Hein Wellens, MD, FAHA, FACC.


This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on August 7, 2008, by the American College of Cardiology Foundation Board of Trustees on May 16, 2008, and by the Heart Rhythm Society Board of Trustees on June 18, 2008.


This article has been copublished in Circulation.

Copies: This document is available on the World Wide Web sites of the American Heart Association (my.americanheart.org), the American College of Cardiology (www.acc.org), and the Heart Rhythm Society (www.hrsonline.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax 212-633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at healthpermissions@elsevier.com.
impaired vascular supply. Alternatively, they may be functional and due to the arrival of a supraventricular impulse during the relative refractory period in a portion of the conducting system, in which case the term aberrant ventricular conduction is applied. They may also be due to abnormal atrioventricular connections, which bypass the atrioventricular node, resulting in ventricular preexcitation.

In 1985, the electrocardiography (ECG) criteria for intraventricular conduction disturbances and ventricular preexcitation were reviewed by an ad hoc working group established by the World Health Organization and the International Society and Federation of Cardiology. Recommendations were made for the diagnosis of complete and incomplete left and right bundle-branch blocks (LBBB and RBBB), left anterior and left posterior fascicular blocks, nonspecific intraventricular blocks, and ventricular preexcitation (3). The purpose of the present report is to define the normal QRS duration, review the recommendations made in 1985, recommend alterations and additions to those recommendations, and provide recommendations for children and adolescents.

**Normal QRS Duration**

The QRS duration depends on the method of measurement, age, and gender. Global intervals, from the earliest onset to the latest offset of the waveform in all leads (generally taken from a spatial vector magnitude or superimposed complexes), are the desirable standard. Global intervals, by definition, will be longer than measurements from single leads. QRS duration may increase with increasing heart size. In addition, the QRS complex is wider in the precordial than in the limb leads. There are also age- and gender-dependent differences in children and adolescents. In children less than 4 years of age, a QRS duration of 90 ms or more is considered to be prolonged, and in those whose ages are 4 to 16 years, a QRS duration of 100 ms or more is considered to be prolonged (4). In adult males, the QRS duration may be up to 110 ms (5). In 725 normal males more than 18 years of age, QRS duration ranged from 74 to 114 ms, with an average of 95 ms (6).

Because global data and data detailing the effects of age, gender, and race are still evolving (7–10), the committee recommends that for the present, a QRS duration of greater than 110 ms in subjects older than 16 years of age be regarded as abnormal. The data for both children and adults may have to be revised in the near future.

**Review of Prior Recommendations With Revisions Proposed by the Committee**

The committee recommends that the definitions and criteria for mean frontal plane electrical axis and axis deviation, R-wave peak time (defined as the interval from the onset of the QRS complex to the peak of the R wave in leads that do not have a small initial R wave, in preference to the term intrinsicoid deflection), complete and incomplete RBBB, complete and incomplete LBBB, left anterior and left posterior fascicular block, nonspecific intraventricular block, ventricular preexcitation, and the Wolff-Parkinson-White pattern and syndrome defined in 1985 (3) be retained, with the inclusion of appropriate values for pediatric subjects, including mean frontal plane axis and axis deviation. These definitions and criteria, with the revisions proposed by the committee, are presented below.

**Mean Frontal Plane Axis**

The mean frontal plane electrical axis, determined by the vector of the maximal (dominant) QRS deflection, depends on age and body habitus (Table). It shifts to the left with increasing age. In adults, the normal QRS axis is considered to be within −30° and 90°. Left-axis deviation is −30° and beyond. Moderate left-axis deviation is between −30° and −45°. Marked left-axis deviation is from −45° to −90° and is often associated with left anterior fascicular block. Moderate right-axis deviation in adults is from 90° to 120°, and marked right-axis deviation, which is often associated with left posterior fascicular block, is between 120° and 180°. In the absence of a dominant QRS deflection, as in an equiphasic QRS complex, the axis is said to be indeterminate.

In children, there is normally a rightward QRS axis at birth that shifts gradually leftward throughout childhood. In the neonate, the mean electrical axis in the frontal plane is between 60° and 190° and is termed “extreme right axis” when it is between −90° and 190°. Normally, the axis then shifts to the left, and by ages 1 to 5 years, it is generally between 10° and 110° (4). Between 5 and 8 years of age, the normal QRS axis may extend to 140°, and between ages 8 and 16 years, the range of QRS axis extends to 120°. Leftward QRS-axis shifts are present in congenital defects with underdevelopment of the right ventricle, such as tricuspid atresia, and with abnormal location of the conduction system, such as complete atrioventricular septal defect.

**Complete RBBB**

1. QRS duration greater than or equal to 120 ms in adults, greater than 100 ms in children ages 4 to 16 years, and greater than 90 ms in children less than 4 years of age.

<table>
<thead>
<tr>
<th>Age</th>
<th>QRS Axis Normal Values</th>
<th>Abnormal Values</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td>−30° to 90°</td>
<td>&lt;−30°</td>
<td>Left-axis deviation</td>
</tr>
<tr>
<td></td>
<td>−30° to −45°</td>
<td>−45° to −90°</td>
<td>Moderate left-axis deviation</td>
</tr>
<tr>
<td></td>
<td>90° to 120°</td>
<td>120° to 180°</td>
<td>Moderate right-axis deviation</td>
</tr>
<tr>
<td>8 to 16 y</td>
<td>0° to 120°</td>
<td>&gt;120°</td>
<td>Right-axis deviation</td>
</tr>
<tr>
<td>5 to 8 y</td>
<td>0° to 140°</td>
<td>&gt;140°</td>
<td>Right-axis deviation</td>
</tr>
<tr>
<td>1 to 5 y</td>
<td>5° to 100°</td>
<td>&gt;100°</td>
<td>Right-axis deviation</td>
</tr>
<tr>
<td>1 mo to 1 y</td>
<td>10° to 120°</td>
<td>&gt;120°</td>
<td>Right-axis deviation</td>
</tr>
<tr>
<td>Neonate</td>
<td>30° to 190°</td>
<td>&gt;190° to −90°</td>
<td>Extreme right-axis deviation</td>
</tr>
<tr>
<td></td>
<td>&lt;30° to &lt;−90°</td>
<td>&lt;−30°</td>
<td>Left-axis deviation</td>
</tr>
</tbody>
</table>
2. rsr', rSR', or rSR in leads V1 or V2. The R' or r' deflection is usually wider than the initial R wave. In a minority of patients, a wide and often notched R wave pattern may be seen in lead V1 and/or V2.
3. S wave of greater duration than R wave or greater than 40 ms in leads I and V6 in adults.
4. Normal R peak time in leads V5 and V6 but greater than 50 ms in lead V1.

Of the above criteria, the first 3 should be present to make the diagnosis. When a pure dominant R wave with or without a notch is present in V1, criterion 4 should be satisfied.

**Incomplete RBBB**
Incomplete RBBB is defined by QRS duration between 110 and 120 ms in adults, between 90 and 100 ms in children between 4 and 16 years of age, and between 86 and 90 ms in children less than 8 years of age. Other criteria are the same as for complete RBBB. In children, incomplete RBBB may be diagnosed when the terminal rightward deflection is less than 40 ms but greater than or equal to 20 ms. The ECG pattern of incomplete RBBB may be present in the absence of heart disease, particularly when the V1 lead is recorded higher than or to the right of normal position and r' is less than 20 ms.

The terms rsr' and normal rsr' are not recommended to describe such patterns, because their meaning can be variously interpreted. In children, an rsr' pattern in V1 and V2 with a normal QRS duration is a normal variant.

**Complete LBBB**
1. QRS duration greater than or equal to 120 ms in adults, greater than 100 ms in children 4 to 16 years of age, and greater than 90 ms in children less than 4 years of age.
2. Broad notched or slurred R wave in leads I, aVL, V5, and V6 and an occasional RS pattern in V5 and V6 attributed to displaced transition of QRS complex.
3. Absent q waves in leads I, V5, and V6, but in the lead aVL, a narrow q wave may be present in the absence of myocardial pathology.
4. R peak time greater than 60 ms in leads V5 and V6 but normal in leads V1, V2, and V3 when small initial r waves can be discerned in the above leads.
5. ST and T waves usually opposite in direction to QRS.
6. Positive T wave in leads with upright QRS may be normal (positive concordance).
7. Depressed ST segment and/or negative T wave in leads with negative QRS (negative concordance) are abnormal (11,12) and are discussed in part VI of this statement.
8. The appearance of LBBB may change the mean QRS axis in the frontal plane to the right, to the left, or to a superior, in some cases in a rate-dependent manner (13,14).

**Incomplete LBBB**
1. QRS duration between 110 and 119 ms in adults, between 90 and 100 ms in children 8 to 16 years of age, and between 80 and 90 ms in children less than 8 years of age without criteria for RBBB or LBBB. The definition may also be applied to a pattern with RBBB criteria in the precordial leads and LBBB criteria in the limb leads, and vice versa.

**Left Anterior Fascicular Block**
1. Frontal plane axis between −45° and −90°.
2. qR pattern in lead aVL.
3. R-peak time in lead aVL of 45 ms or more.
4. QRS duration less than 120 ms.

These criteria do not apply to patients with congenital heart disease in whom left-axis deviation is present in infancy.

**Left Posterior Fascicular Block**
1. Frontal plane axis between 90° and 180° in adults. Owing to the more rightward axis in children up to 16 years of age, this criterion should only be applied to them when a distinct rightward change in axis is documented.
2. rS pattern in leads I and aVL.
3. qR pattern in leads III and aVF.
4. QRS duration less than 120 ms.

**Ventricular Preexcitation of Wolff-Parkinson-White Type**
Whether preexcitation is full or not cannot be determined from the body surface ECG, but the following criteria are suggestive of full preexcitation:

1. PR interval (assuming no intra-atrial or interatrial conduction block) less than 120 ms during sinus rhythm in adults and less than 90 ms in children.
2. Slurring of initial portion of the QRS complex (delta wave), which either interrupts the P wave or arises immediately after its termination.
3. QRS duration greater than 120 ms in adults and greater than 90 ms in children.
4. Secondary ST and T wave changes.

**Terms Not Recommended**
The term Mahaim-type preexcitation is not recommended because the diagnosis cannot be made with certainty on the basis of the surface ECG. The terms atypical LBBB, bilateral bundle-branch block, bifascicular block, and trifascicular block are not recommended because of the great variation in anatomy and pathology producing such patterns. The committee recommends that each conduction defect be described separately in terms of the structure or structures involved instead of as bifascicular, trifascicular, or multifascicular block.

The term Brugada pattern to describe a pattern that simulates incomplete RBBB in lead V1 with ST-segment changes is not recommended for incorporation into automated interpretative algorithms because there are 3 different types of ST-segment changes (15,16) and because the pattern is not specific for the Brugada syndrome. The use of this term should be left to the discretion of the overreader.

The term left septal fascicular block is not recommended because of the lack of universally accepted criteria.

---

978 Surawicz et al. Standardization and Interpretation of the ECG, Part III


---

Downloaded from content.onlinejacc.org by Darryn Appleton on August 2, 2011
Additional Terms

Peri-infarction block (17,18): The term possible peri-infarction block is recommended when, in the presence of an abnormal Q wave generated by a myocardial infarction in the inferior or lateral leads, the terminal portion of the QRS complex is wide and directed opposite to the Q wave (i.e., a QR complex in the inferior or lateral leads).

Peri-ischemic block (19,20): This term is recommended when a transient increase in QRS duration accompanies the ST-segment deviation seen with acute injury.

Disclosures

Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/Honoraria</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>James J. Bailey</td>
<td>National Institutes of Health</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rory Childers</td>
<td>University of Chicago</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Barbara J. Deal</td>
<td>Northwestern University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Leonard S. Gettes</td>
<td>University of North Carolina</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Anton Gorgels</td>
<td>University Hospital Maastricht</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>E. William Hancock</td>
<td>Stanford University Medical Center (retired Professor Emeritus)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Philips Medical Systems†; Covance Diagnostics†</td>
<td>None</td>
</tr>
<tr>
<td>Mark Josephson</td>
<td>Harvard Medical Faculty Physicians for Beth Israel Deaconess Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic*</td>
<td>None</td>
</tr>
<tr>
<td>Paul Kligfield</td>
<td>Weill Medical College of Cornell University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Philips Medical†; Mortara Instrument†; GE Healthcare†; MDS Pharma Services†; Cardiac Science*</td>
<td>None</td>
</tr>
<tr>
<td>Jan A. Kors</td>
<td>Erasmus Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Welch Allyn*</td>
</tr>
<tr>
<td>Peter Macfarlane</td>
<td>University of Glasgow</td>
<td>Cardiac Science Corp†; Medtronic Physio Control†; Spacelabs Health Care†; Draeger Medical†; Heartlab†; McKesson†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cardiac Science Corp†; Medtronic Physio Control†; Spacelabs Health Care†; Draeger Medical†; Heartlab†; McKesson†</td>
<td>None</td>
</tr>
<tr>
<td>Jay W. Mason</td>
<td>Independent Consultant</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David M. Mirvis</td>
<td>University of Tennessee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter Okin</td>
<td>Weill Medical College of Cornell University</td>
<td>Merck &amp; Co, Inc†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Olle Pahlm</td>
<td>BFC Klin</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Pentti M. Rautaharju</td>
<td>Wake Forest University Medical School (retired)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Borys Surawicz</td>
<td>CARE Group</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gerard van Herpen</td>
<td>Erasmus Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Galen S. Wagner</td>
<td>Duke University Medical Center</td>
<td>Medtronic†; Physiocontrol†; Welch Allyn†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Writing Group Disclosures, Continued

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/Honoraria</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hein Wellens</td>
<td>University of Maastricht</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic*</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.

### Reviewer Disclosures

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey L. Anderson</td>
<td>Intermountain Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Leonard S. Dreifus</td>
<td>Hahnemann University Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mark Eisenberg</td>
<td>McGill University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Nora Goldschlager</td>
<td>University of California, San Francisco</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cindy Grines</td>
<td>William Beaumont Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mark Hlatky</td>
<td>Stanford University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter Kowey</td>
<td>Lankenau Medical Office</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>CardioNet†</td>
<td>Transoma†; CardioNet†; NewCardio*</td>
<td>None</td>
</tr>
<tr>
<td>Rachel Lampert</td>
<td>Yale University</td>
<td>Medtronic†; Guidant/Boston Scientific†; St. Jude†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic*</td>
<td>None</td>
</tr>
<tr>
<td>Robert Lichtenberg</td>
<td>Heart Care Centers of Illinois</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jonathan Lindner</td>
<td>Oregon Health and Sciences University</td>
<td>Genentech*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Genentech*; VisualSonics*</td>
<td>None</td>
</tr>
<tr>
<td>Frank Marcus</td>
<td>University of Arizona</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert J. Myerburg</td>
<td>University of Miami</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gerald M. Pohost</td>
<td>University of Southern California, Keck School of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard Schofield</td>
<td>University of Florida Health Sciences Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samuel Shubrooks</td>
<td>Beth Israel Deaconess Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John Strobel</td>
<td>IMA, Inc</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Boston Scientific*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stuart A. Winston</td>
<td>Michigan Heart, PC</td>
<td>Medtronic*; Boston Scientific*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.
References


Key Words: ACCF Expert Consensus Documents electrocardiography electrophysiology conduction IVCD.
This information is current as of August 2, 2011

Updated Information & Services
including high-resolution figures, can be found at:
http://content.onlinejacc.org/cgi/content/full/53/11/976

References
This article cites 18 articles, 6 of which you can access for free at:
http://content.onlinejacc.org/cgi/content/full/53/11/976#BIBL

Citations
This article has been cited by 3 HighWire-hosted articles:
http://content.onlinejacc.org/cgi/content/full/53/11/976#otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Expert Consensus Documents
http://content.onlinejacc.org/cgi/collection/expert_consensus

Rights & Permissions
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://content.onlinejacc.org/misc/permissions.dtl

Reprints
Information about ordering reprints can be found online:
http://content.onlinejacc.org/misc/reprints.dtl